Fulvestrant 250 mg Injection

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Fulvestrant 250 mg Injection pre-filled syringe pack

Product Overview

Fulvestrant 250 mg Injection contains fulvestrant, an estrogen receptor antagonist. Its labelling describes it as a treatment for hormone receptor-positive breast cancer, acting by blocking the effect of estrogen on breast cancer cells and thereby described as slowing their growth.

Active ingredient
Fulvestrant
Dosage form
Solution for intramuscular injection (pre-filled syringe)
Therapeutic class
Estrogen receptor antagonist (antineoplastic)
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with fulvestrant and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Described for the treatment of hormone receptor-positive breast cancer
  • Described as blocking estrogen activity in breast cancer cells
  • Dose and duration are set by the treating doctor according to the stage of disease
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Administered only by a doctor or nurse as a slow intramuscular injection
  • Given on the schedule set by the treating specialist
  • Not intended for self-administration

Described Side Effects

Commonly described side effects include:

  • Nausea, vomiting or constipation
  • Injection-site pain
  • Fatigue and weakness
  • Hot flushes
  • Loss of appetite
  • Bone, joint or muscle pain
  • Headache
  • Cough or breathlessness

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Liver or kidney disease should be disclosed to the doctor before treatment
  • Bleeding disorders or use of anticoagulants should be disclosed, as injections may cause bruising or bleeding
  • Pregnancy, planned pregnancy or breastfeeding should be discussed with the prescriber
  • Persistent or severe reactions should be reported promptly

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling it contains fulvestrant and is described for hormone receptor-positive breast cancer, blocking estrogen’s effect on cancer cells. SDO Pharma has not independently verified these claims.

Its labelling states it is given by a healthcare professional as an intramuscular injection; it is not intended for self-administration.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services